Proactive Investors - Run By Investors For Investors

AstraZeneca’s Lynparza set for EU approval as advanced ovarian cancer maintenance treatment

70% of women with ovarian cancer relapse after successful chemo, but Lynparza has been shown to significantly reduce that rate
ovarian cancer
Lynparza has already been approved for this indication in the US

AstraZeneca PLC’s (LONP:AZN) Lynparza drug has been recommended for approval in the EU as a first-line maintenance treatment for women with advanced ovarian cancer.

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of the drug, meaning it will recommend that the European Medicines Agency approve it.

The recommendation is for the use of Lynparza tablets in adult women with advanced ovarian cancer who have responded to an initial round of chemotherapy.

READ: Astra sees profits double in Q1

Regulators based their opinion on data from the SOLO-1 trial, which showed the pills reduced the risk of disease progression or death by 70% compared to placebo following response to chemo.

Of those patients receiving Lynparza, 60% of women remained progression-free after three years versus 27% in the placebo arm.

“There remains a significant unmet need in the treatment of advanced ovarian cancer as 70% of women globally relapse within the first three years after their initial treatment,” said Astra’s oncology boss Dave Fredrickson.

“The results of SOLO-1 demonstrate the potential of using Lynparza earlier in the treatment pathway as a maintenance therapy, and reinforce the importance of identifying a patient's BRCA mutation status as soon as they are diagnosed.”

Chief medical officer Roy Baynes added: “If approved, this expanded indication could change the way women in Europe with BRCA-mutated advanced ovarian cancer are treated.”

In a note to clients, analysts at Shore Capital commented: "Our analysis suggests that consensus estimates for Collaboration Revenue to 2024F are covered by potential milestones from the Merck-Lynparza collaboration alone, although AstraZeneca has several agreements which can also contribute to this revenue line. Hence, we are comfortable with consensus estimates for Collaboration Revenue."

Astra shares were 1.1% to 5,857p in afternoon trade on Monday.

 -- Adds analysts comment, updates share price --

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use